About 200 reports

The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...

  • Dementia
  • Pharmaceutical
  • Healthcare
  • World
  • Europe
  • North America
  • APAC
  • Dementia Prevalence
  • Health Expenditure

Global Dementia And Movement Disorder Treatment Market 2022-2026 The analyst has been monitoring dementia and movement disorder treatment market and it is poised to grow by $ 7.14 bn during 2022-2026, accelerating at a CAGR of 6.95% during the forecast period. Our report on the dementia and movement disorder treatment market...

  • Gene Therapy
  • Dementia
  • Marketing Research
  • Biomarker
  • Medical Biotechnology
  • World

Vascular Dementias (Central Nervous System) - Drugs in Development, 2021 Summary Vascular Dementias (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Neurology
  • Dementia
  • World

Dementia Associated With Alzheimer’s Disease (Central Nervous System) - Drugs in Development, 2021 Summary Dementia Associated With Alzheimer’s Disease (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Dementia Associated With Alzheimer’s Disease pipeline landscape. The...

  • Dementia
  • Neurology
  • World

The blood brain barrier technologies market is expected to reach US$ 5,101.94 million by 2028 from US$ 1,041.05 million in 2021; it is estimated to register a CAGR of 25.5% from 2021 to 2028. Growing prevalence of neurological disorders, and increasing geriatric population and rising prevalence of age-associated neurological disorders are...

  • Mental Health
  • Neurological Disorder
  • Dementia
  • Psychotic Disorder
  • Pharmaceutical
  • Infectious Disease
  • Research And Development
  • World
  • APAC
  • Europe
  • Dementia Prevalence
  • Health Expenditure

The South and Central America nurse call systems market is expected to reach US$ 200.11 million by 2027 from US$ 87.23 million in 2019. The market is estimated to grow at a CAGR of 10.8% from 2020-2027. The growth of the South and Central America nurse call systems market is driven by the growing incidence of Alzheimer’s disease and dementia...

  • Pathology
  • Cell Therapy
  • Regenerative Medicine
  • Drug Development
  • Infectious Disease
  • Molecular Biology
  • Central America
  • Chronic Disease Prevalence
  • Practising Nurses And Midwives

Major players in the alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd. The global alzheimer’s disease treatment market is expected to grow from $4.71 billion in 2021 to $5.08 billion in 2022 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd. The global alzheimer’s disease treatment market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...

  • Dementia
  • World
  • Health Expenditure
  • Dementia Prevalence

Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd. The global Alzheimer’s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual...

  • Dementia
  • World
  • United States
  • Dementia Incidence
  • Dementia Prevalence

Global Psychiatry Partnering 2015 to 2022 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015. Trends in Psychiatry partnering deals Financial deal terms for headline, upfront and royalty by stage of development Psychiatry partnering...

  • Neurological Disorder
  • Anxiety Disorder
  • Dementia
  • Sleep Aid
  • Personality Disorder
  • World

Major players in the nanomedicine market are Pfizer Inc., Nanotherapeutics Inc., NanoViricides Inc, Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, Merck AG, Ablynx NV, F. Hoffmann-La Roche AG, Nanospectra Biosciences and GE Healthcare. The global nanomedicine market is expected to grow from $221.12 billion in 2021 to $252.50...

  • Nanotechnology
  • Chronic Disease
  • World
  • APAC
  • United States
  • Cancer Incidence
  • Nanotechnology Revenue

INTRODUCTION Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US. Presently, more...

  • Dementia
  • Therapy
  • APAC
  • Europe
  • North America

"US Alzheimer’s Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights: • US Alzheimer’s Disease Drug Market Opportunity: > US$ 5 Billion • US Accounts For More Than 40% of Global Alzheimer’s Disease Drug Market • US Alzheimer’s Disease Drug Clinical Trials: 200 Drugs in Pipeline •...

  • Dementia
  • United States
  • Drug Approval

Major players in the nanomedicine market are Pfizer Inc., Nanotherapeutics Inc., NanoViricides Inc, Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, Merck AG, Ablynx NV, F. Hoffmann-La Roche AG, Nanospectra Biosciences, GE Healthcare, Gilead Sciences Inc., Novartis AG, Amgen Inc., and Sanofi. The global nanomedicine market...

  • Nanotechnology
  • Chronic Disease
  • Biopharmaceutical
  • Infectious Disease
  • Nanoparticle
  • World
  • APAC
  • United States
  • Cancer Incidence
  • Nanotechnology Revenue

Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019. The market is projected to grow with a CAGR of 8.1% from 2020-2027. The rare neurological disease treatment market is growing primarily due to the rising prevalence of rare neurological diseases, increasing...

  • Neurological Disorder
  • Europe
  • Dementia Prevalence
  • Drug Approval

Asia Pacific, the rare neurological disease treatment market, is anticipated to reach US$ 2,437.02 Mn in 2027 from US$ 1,225.38 Mn in 2019. The market is projected to grow with a CAGR of 9.2% from 2020-2027. The rare neurological disease treatment market is growing primarily due to the rising prevalence of rare neurological diseases,...

  • Neurological Disorder
  • APAC
  • Dementia Prevalence
  • Elderly Population

Orexin Receptor Type 1 - Drugs In Development, 2021 Summary Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in...

  • Pharmaceutical
  • Therapy
  • Drug Development
  • Eating Disorder
  • World
  • Illicit Drug Use
  • Drug Approval

Orexin Receptor Type 2 - Drugs In Development, 2021 Summary According to the recently published report ’Orexin Receptor Type 2 - Drugs In Development, 2021’; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately...

  • Pharmaceutical
  • Sleep Aid
  • Mental Health
  • World
  • Prescription Drug Sales
  • Pharmaceutical Registrations

Major players in the neurosurgery devices and equipment market are Medtronic, Boston Scientific Corporation, Stryker, Conmed Corporation and Smith & Nephew. The global neurosurgery devices and equipment market is expected to grow from $3.14 billion in 2020 to $3.55 billion in 2021 at a compound annual growth rate (CAGR) of 13.1%. The...

  • Surgical Equipment
  • Neurological Disorder
  • United States
  • Drug Approval

Contrast Injector Systems Market By Product Type (Consumables, Injector Systems, Accessories), By Application (Radiology, Interventional Radiology, Interventional Cardiology), By End User (Hospitals, Diagnostics centers, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030 Contrast injector...

  • Diagnostic Imaging
  • Chronic Disease
  • Magnetic Resonance Imaging
  • World
  • Chronic Disease Prevalence

Alpha Synuclein - Pipeline Review, H1 2020 Summary According to the recently published report ’Alpha Synuclein – Pipeline Review, H1 2020’; Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 57 molecules....

  • Psychotic Disorder
  • World
  • Diagnostic Imaging Density
  • Lead Price

Alzheimer’s Disease: Epidemiology Forecast to 2028 Summary Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly.AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities...

  • Dementia
  • World
  • Dementia Prevalence
  • Elderly Population

Brain Health Supplements Market Size, Share & Trends Analysis Report By Product (Natural Molecules, Herbal Extract), By Application, By Region, And Segment Forecasts, 2022 - 2030 Brain Health Supplements Market Growth & Trends The global brain health supplements market size is expected to...

  • Dietary Supplement
  • Mental Health
  • World
  • North America

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2020 Summary 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic...

  • Drug Development
  • Dementia
  • Hormone
  • Pharmaceutical
  • World
  • Diagnostic Imaging Density

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha...

  • Pharmaceutical
  • Therapy
  • Neurological Disorder
  • World
  • Diagnostic Imaging Density

The Global Wireless Brain Sensors Market size is expected to reach $679 Million by 2026, rising at a market growth of 12.8% CAGR during the forecast period. The growing adoption of inactive lifestyles across the world is one of the primary factors fueling the market for wireless brain sensors. Unhealthy lifestyle decisions, for example, alcohol...

  • Neurological Disorder
  • Neurological Monitoring
  • Psychotic Disorder
  • World
  • APAC
  • North America
  • Europe
  • Cause-Specific Mortality Rate
  • Health Expenditure

KEY FINDINGS The global bone densitometer market growth is anticipated to progress at a CAGR of 4.30% during the forecast period, 2022-2030. The market growth is attributed to technological advancements like DXA scanners, the rising degenerative joint diseases, the increasing prevalence of osteoporosis, and the growing...

  • Bone Densitometer
  • Musculoskeletal Disorder
  • World
  • Life Expectancy

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Drugs In Development, 2021 Summary According to the recently published report ’Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Drugs In Development, 2021’; Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)...

  • Pharmaceutical
  • Therapy
  • Neurological Disorder
  • Neurology
  • Psychotic Disorder
  • World
  • Diagnostic Imaging Density

Cognitive and Memory Enhancer Drugs Market by Product (Aricept, Exelon, Namenda, Razadyne, Provigil, Ritalin, Adderall, and Others), Application (Disease Treatment Education, Sports, and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030 The global cognitive and memory enhancer drug market...

  • Neurological Disorder
  • World
  • APAC